Heparan sulfate proteoglycans
Heparan sulphate proteoglycans are a family of sugar-chain-bearing proteins distributed throughout the dermal extracellular matrix and at the dermo-epidermal junction. They serve as the primary storage reservoir for growth factors including FGF2, FGF7, FGF10, and VEGF, holding them in a protected, bioavailable form until tissue repair demand releases them. UVB exposure and MMP-driven ECM degradation both deplete this reservoir, reducing the skin’s regenerative capacity independently of growth factor synthesis.
Heparan sulphate proteoglycans (HSPGs) are a family of proteins characterised by the presence of covalently attached heparan sulphate glycosaminoglycan (GAG) chains – long, differentially sulphated sugar chains that provide the molecular structure through which HSPGs bind, retain, and regulate a wide range of signalling proteins in the extracellular environment. [7] The family includes both extracellular matrix-resident members and transmembrane members: in skin, the most clinically relevant are perlecan (ECM and basement membrane), syndecan-1, -2, and -4 (transmembrane, cell surface), and agrin (basement membrane). [4] Each has a distinct core protein, a distinct tissue distribution, and a distinct set of binding partners, but all share the heparan sulphate chains that confer their growth factor storage and signalling regulation functions.
| Entity | Location | Primary Core Protein | Biological Function |
|---|---|---|---|
| Perlecan | ECM / Basement Membrane | HSPG2 | The “Depot”: High-capacity growth factor storage. |
| Syndecans | Cell Surface (Fibroblasts) | Syndecan-4 | The “Integrator”: Co-receptor for signalling. |
| Agrin | Basement Membrane (DEJ) | Agrin | Structural support and DEJ integrity. |
Perlecan: The Dermal Growth Factor Depot
Perlecan (formally HSPG2) is one of the largest ECM molecules in the body, with a five-domain structure exceeding 200nm and an evolutionary history predating vertebrates. [3] It is the dominant HSPG in the dermal ECM and basement membrane, and its heparan sulphate chains – located primarily in domain I – function as what primary research has explicitly described as an “on-site depot to assist with rapid repair” of tissue borders when compromised by wounding. [3] FGF2, FGF7, FGF10, and VEGF all bind to perlecan’s heparan sulphate chains with relatively slow off-rates – meaning growth factors, once bound, stay bound until an enzymatic release signal is provided. [2] In practical terms, this means the dermal ECM isn’t simply a structural scaffold but an active repository of repair-ready signalling molecules, maintained in proximity to the cells that need them precisely when tissue disruption creates the release signal.
The release mechanism itself is biologically elegant: MMPs including stromelysin ( MMP-3) and collagenase, along with the enzyme heparanase, cleave the heparan sulphate chains of perlecan, releasing bound growth factors locally at sites of tissue injury or remodelling. Controlled MMP activity at a wound site therefore simultaneously degrades damaged structural matrix and releases the repair signals stored within it. This dual function makes some level of MMP activity genuinely necessary rather than simply destructive.
Syndecans: Cell-Surface Signalling Integrators
Whilst perlecan is ECM-resident, the syndecan family occupies the cell surface – transmembrane HSPGs that span the membrane with their core proteins, presenting heparan sulphate chains extracellularly to bind growth factors and ECM components, whilst their intracellular tails connect to the cytoskeleton and activate intracellular signalling cascades. [8] Syndecan-4 in particular acts as a co-receptor for growth factors, stabilising their interaction with primary signalling receptors on the cell surface and simultaneously regulates cytoskeletal organisation, cell adhesion, and migration through Rho GTPase and PKCα activation. [1]
This co-receptor function is not passive: HSPGs actively modulate the competitive balance between different heparin-binding growth factors at the cell surface. FGF2 and heparin-binding EGF (HB- EGF), for example, can cross-regulate each other’s receptor binding through HSPG stabilisation, meaning the local HSPG environment shapes which growth factor signals reach their receptors, and at what intensity, even when multiple signals are present simultaneously. [5] This regulatory function means HSPG density and sulphation pattern aren’t just growth factor storage variables but active determinants of how growth factor signals are prioritised and integrated at the cell surface.
How UV Exposure Depletes the HSPG Reservoir
The relationship between UV irradiation and HSPG depletion is one of the clearest mechanistic links between photoageing and impaired regenerative capacity in skin. UVB irradiation activates heparanase – the primary enzyme responsible for cleaving heparan sulphate chains – in keratinocytes. In UVB-irradiated human skin, the heparan sulphate chains of perlecan are markedly degraded at the dermo-epidermal junction, producing a significant reduction in binding capacity for FGF2, FGF7, and VEGF at the basement membrane. [6] This degradation is not confined to acute exposure: heparan sulphate is measurably depleted in chronically sun-exposed skin relative to sun-protected skin of the same individual, confirming that cumulative UV exposure progressively erodes the DEJ growth factor reservoir over years.
This means that significantly photodamaged skin is not simply deficient in collagen and elastin. It is also deficient in the molecular infrastructure that stores and deploys the growth factors needed to repair that structural deficit. Stimulating fibroblast activity through professional treatments delivers growth factor signals into a tissue where the normal HSPG-mediated retention and regulatory machinery has been partially dismantled – signals that clear faster, anchor less securely, and compete less effectively for receptor occupancy than they would in an intact dermal ECM.
The “Signalling Depot” Status
| Dermal State | HSPG Integrity | FGF/VEGF Binding | Clinical Presentation |
|---|---|---|---|
| Intact (Young) | High Density | Strong / Sustained | Rapid healing; robust response to iPRF. |
| Photoaged | Cleaved (Heparanase+) | Weak / Leaky | Attenuated response; growth factors “wash out.” |
| Inflamed | Degraded (MMP-3+) | Disrupted | Persistent structural loss; poor repair capacity. |
HSPGs, Ageing, and the ECM Degradation Feedback
The broader picture of HSPG decline in ageing skin involves two concurrent routes. First, MMP-driven ECM degradation (as the Reticular Dermis and MMP entities describe) progressively degrades the proteoglycan network alongside collagen and elastin, reducing perlecan density and heparan sulphate chain availability. Second, the synthesis capacity for glycosaminoglycan chains declines in senescent fibroblasts, reducing the production of new HSPG to replace what is being degraded. [7] Together these create a compounding deficit in the growth factor reservoir that parallels the structural matrix loss and which, unlike collagen loss, is not currently a direct target of any single treatment modality in the Creative Touch portfolio.
Clinical Application
HSPGs don’t have a treatment entity of their own in the way that collagen, elastin, or ceramides do. There is no injectable HSPG, no topical that directly restores heparan sulphate chain density in the dermis. Their clinical significance is rather as a framework for understanding why certain treatment combinations work better than their individual mechanisms would predict, and why photodamaged skin responds differently to growth factor delivery than skin where the ECM is more intact.
Why this matters for iPRF outcomes
The HSPG reservoir context is the missing piece in understanding why iPRF produces more variable results in significantly photodamaged or aged skin than in younger, less-damaged tissue. When perlecan’s heparan sulphate chains have been depleted by chronic UV exposure or MMP-driven proteoglycan degradation, the FGF2, FGF7, and VEGF delivered in the iPRF preparation have fewer anchoring sites in the treated tissue. [6] Growth factors clear faster, the sustained signalling that the fibrin matrix was extending becomes less well-supported by the tissue itself, and the overall regenerative response is attenuated. This is a Tier 4 mechanistic inference – it follows logically from established HSPG biology and is not yet directly demonstrated in aesthetic treatment studies – but it is mechanistically coherent and clinically worth understanding when setting realistic expectations for iPRF in heavily photodamaged skin.
The MMP suppression connection
The most direct route to HSPG preservation available in the Creative Touch portfolio is MMP suppression, specifically through polynucleotides’ NF-κB-mediated reduction of MMP-1, MMP-3, and MMP-9. MMP-3 (stromelysin) is one of the enzymes capable of cleaving perlecan’s heparan sulphate chains to release bound growth factors. Controlled MMP-3 activity at a wound site is part of normal repair; chronically elevated MMP-3 in photoaged or inflamed skin progressively depletes the perlecan reservoir without the wound-healing context that would justify it. Suppressing this chronic MMP-3 elevation through polynucleotides therefore protects not only structural collagen and elastin but also the growth factor depot infrastructure- a benefit that isn’t visible in collagen density measurements alone but contributes to the durability of the improved tissue environment polynucleotides create.
Practical protocol implications
Understanding HSPGs suggests a more nuanced treatment sequencing rationale than simple “environment first, stimulation second.” For significantly photodamaged clients where HSPG depletion at the DEJ is likely, the most productive protocol logic is:
- Polynucleotides first – to suppress the MMP activity actively depleting residual HSPG, and to restore the macrophage-fibroblast environment that sustains proteoglycan synthesis
- HA skin boosters – hyaluronic acid injection activates fibroblast mechanoreception and synthetic output, which includes glycosaminoglycan synthesis alongside collagen, supporting partial HSPG replenishment from the production side
- iPRF subsequently – into a tissue environment where both MMP-driven depletion has been slowed and fibroblast synthetic capacity has been stimulated, meaning the delivered growth factors encounter improved matrix retention conditions
This isn’t a rigid protocol prescription. It is the mechanistic rationale that explains why this sequence tends to produce more durable outcomes than iPRF alone or iPRF first in significantly aged and photodamaged presentations.
Clinical Strategy for HSPG Preservation
| Clinical Goal | Targeted Mechanism | Treatment Choice |
|---|---|---|
| Stop Depletion | MMP-3 & NF-B Inhibition | Polynucleotides |
| Refill Reservoir | Exogenous FGF/VEGF Supply | iPRF |
| Stimulate Synthesis | Mechanoreception GAG production | HA Skin Boosters |
| Homecare Protection | ROS Neutralisation (AP-1 suppression) | Vitamin C / SPF |
References
Chung H, Multhaupt HA, Oh ES, et al. (2016). Minireview: Syndecans and their crucial roles during tissue regeneration. FEBS Lett, 590(15), 2408-17 . doi.org/10.1002/1873-3468.12280
Clyne AM, Edelman ER (2009). Vascular growth factor binding kinetics to the endothelial cell basement membrane, with a kinetics-based correction for substrate binding. Cytotechnology, 60(1-3), 33 . doi.org/10.1007/s10616-009-9212-1
Farach-Carson MC, Warren CR, Harrington DA, et al. (2014). Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders. Matrix Biol, 34, 64-79 . doi.org/10.1016/j.matbio.2013.08.004
Farrugia BL, Melrose J (2023). The Glycosaminoglycan Side Chains and Modular Core Proteins of Heparan Sulphate Proteoglycans and the Varied Ways They Provide Tissue Protection by Regulating Physiological Processes and Cellular Behaviour. Int J Mol Sci, 24(18) . doi.org/10.3390/ijms241814101
Forsten-Williams K, Chu CL, Fannon M, et al. (2008). Control of growth factor networks by heparan sulfate proteoglycans. Ann Biomed Eng, 36(12), 2134-48 . doi.org/10.1007/s10439-008-9575-z
Iriyama S, Matsunaga Y, Takahashi K, et al. (2011). Activation of heparanase by ultraviolet B irradiation leads to functional loss of basement membrane at the dermal-epidermal junction in human skin. Arch Dermatol Res, 303(4), 253-61 . doi.org/10.1007/s00403-010-1117-5
Kirn-Safran C, Farach-Carson MC, Carson DD (2009). Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans. Cell Mol Life Sci, 66(21), 3421-34 . doi.org/10.1007/s00018-009-0096-1
Lambaerts K, Wilcox-Adelman SA, Zimmermann P (2009). The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol, 21(5), 662-9 . doi.org/10.1016/j.ceb.2009.05.002
Also Known As
- heparan sulfate proteoglycan
- heparan sulphate proteoglycan
- heparan sulphate proteoglycans
- HS-PGs
- HSPG
- HSPGs
Biological Relationships
Biological Interactions
- Stimulates Vascular endothelial growth factor
- Has component Vascular endothelial growth factor Evidence: HSPGs (particularly perlecan) store VEGF as ECM-bound reservoir for controlled slow-release; VEGF binds HSPG in dermis. PMC4046116.
- Requires Fibroblast growth factor
Influenced By
- this Stimulated by Polynucleotides
- this Inhibited by Matrix metalloproteinase Evidence: MMP activity degrades HSPG core proteins depleting ECM growth factor reservoir; MMP-overactive skin progressively depletes HSPG-bound VEGF. PMC4046116.